South America Neurotoxins Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product Type (Botox, Dysport, Xenomin, and Others), Application (Therapeutic and Aesthetic), and End User (Hospitals, Specialty Clinics, Dermatology Clinics, and Others)
The South America neurotoxins market is expected to grow from US$ 280.48 million in 2023 to US$ 525.57 million by 2028. It is estimated to register a CAGR of 13.4% from 2023 to 2028.
Emergence of Innovative Facial Aesthetic Products Fuels South America Neurotoxins MarketThe overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of DTX-021—a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the South America neurotoxin market to grow.
South America Neurotoxins Market OverviewThe South America neurotoxin market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Growth in this market is mainly driven by the growing adoption of minimally invasive and non-invasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, availability of technologically advanced & user-friendly products, and increasing demand for aesthetic treatments. The regional market is likely to propel during the forecasted period owing to the recent technological developments that have made a direct impact on the economy of Brazil that has advanced to a large extent. In Brazil, the adoption of minimally invasive and non-invasive cosmetic procedures with a broad range of indications, such as botulinum-toxin-based treatment, are the major market drivers. The brand names of botulinum toxin A formulations available in Brazil involve Botox, Xeomin, Dysport, Botulift, and Prosigne. Additionally, the International Society of Aesthetics and Plastic Surgeons (ISAPS) 2018 report reveals that botulinum toxin-based treatment was the most common non-surgical procedure performed in Brazil, accounting for 51% (approx. 392,530) of the total non-surgical procedures. The cost savings advantage and higher work efficiencies achieved are cited as the major attracting points for manufacturing companies to establish bases in South America.
South America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)
South America Neurotoxins Market SegmentationThe South America neurotoxins market is segmented into product type, application, end user, and country.
Based on product type, the South America neurotoxins market is subsegmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the South America neurotoxins market is segmented into therapeutic and aesthetic. The aesthetic segment held a larger market share in 2023.
Based on end user, the South America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the South America neurotoxins market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Brazil dominated the market share in 2023.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA are among the leading companies operating in the South America neurotoxins market.
Reasons to BuySave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South America neurotoxins market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South America neurotoxins market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South America market trends and outlook coupled with the factors driving the neurotoxins market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution